Elevate Research Community retweeted
Why Nattokinase is the one supplement almost every TRT & AAS user Is still underdosing
Nattokinase is one of the first supplements the bro community tells you to grab when you hop on TRT. Most guys either buy the standard 2,000 FU bottle and call it a day, or they take it without actually understanding what it does. Either way, they’re usually leaving the real benefits on the table.
It’s even more relevant if you’re enhanced. AAS push the same blood-thickening effects as TRT (higher hematocrit and viscosity aren’t inherently bad-that’s part of how androgens work), but they raise the stakes on clotting risk and cardiovascular strain. Nattokinase is one of the cheapest, most practical tools you can add to keep blood moving better while you’re on.
I run around 10,000 FU a day and have for years.
What it actually is
Nattokinase is an enzyme produced when Bacillus subtilis ferments soybeans into natto. It’s a serine protease with strong fibrinolytic activity, meaning it helps break down fibrin, the protein mesh that holds blood clots together. It’s measured in fibrinolytic units (FU), not milligrams. A 100 mg capsule can be 2,000 FU or far less depending on potency, so always check the FU number.
How it works
It works through multiple mechanisms:
-Directly degrades fibrin.
-Boosts tissue plasminogen activator (tPA) activity and inhibits PAI-1 (the main brake on the body’s own clot-dissolving system).
-Lowers clotting factors VII and VIII.
-Reduces red blood cell aggregation and whole-blood viscosity.
The net effect is better blood fluidity and less fibrin buildup without acting like a pharmaceutical anticoagulant.
Why it matters on TRT and AAS
Testosterone and other androgens stimulate red blood cell production. Hematocrit rises, blood gets thicker, and the risk of micro-clots or higher cardiac workload goes up. Nattokinase doesn’t reliably lower hematocrit the way phlebotomy or dose adjustments do, don’t treat it as a replacement for managing high HCT properly, but it supports the fibrinolysis side of the equation and helps keep blood from getting sticky. That matters more the higher your dose and the longer you’re on.
Beyond that, the data shows broader cardiovascular support. A large 12-month clinical study using 10,800 FU/day reported roughly 36% reduction in carotid plaque area, about 22% reduction in carotid intima-media thickness, and solid lipid shifts (LDL down ~18%, HDL up ~16%). The same study found 3,600 FU/day did essentially nothing for those markers. Smaller trials show modest blood pressure reductions at lower doses (around 2,000 FU).
Most commercial products are dosed at 2,000 FU because that’s the amount used in the early blood pressure studies and what the Japanese Nattokinase Association recommends as a baseline. For the stronger effects seen on plaque and lipids, the higher end (closer to 6,000-10,800 FU) is what the data points to.
Take it on an empty stomach for better absorption. Look for products standardized to FU, preferably third-party tested for activity. It’s generally well-tolerated at the doses studied (including 10,800 FU), but it has real fibrinolytic activity, so don’t stack it with prescription anticoagulants or antiplatelets as much if you can truly avoid it. This gives you a cheap, evidence-backed edge on the clotting and viscosity side of the equation that androgens create.
For the price, it’s one of the higher-leverage additions to a TRT or enhanced protocol. Most people just underdose it.
Elevate Research Community retweeted
Tropisetron blocks 5-HT3 and partially activates alpha7 nicotinic receptors. Two receptor families, one molecule. kimerachems.co/library/tropi…
Elevate Research Community retweeted
Replying to @hubermanlab
certified by who is the real question. lot-level testing with public results would matter way more than where it was made.
Elevate Research Community retweeted
Sneak Peak to complete website overhaul. No one will have a website like this in the industry. Completely built on our own custom platform.
Elevate Research Community retweeted
Caffeine makes you better at doing while making you worse at thinking.
Yes, caffeine can increase dopamine release, elevate mood, improve alertness & reaction time.
But its benefits are strongest for tasks requiring speed, not tasks requiring intellectual power.
Research described by Stephen Cherniske — biochemist and author of Caffeine Blues — found that assembly-line type work can improve on caffeine while more complex reasoning gets worse.
Michael Pollan — author and journalist, who abstained from caffeine for 3 months as part of his research for This Is Your Mind on Plants — noticed this firsthand when he drank coffee again for the first time.
He described himself as compulsively getting things done, focusing on each task with single-minded intensity.
“Another task suddenly demanded my attention: it was time to tackle my closet. This is not something I have ever done of my own free will, but at that moment I wanted nothing more than to take all my sweaters off the shelf and sort them into four piles.”
That same trade-off shows up in memory research.
In one study, non-habitual caffeine users received 0, 100, 200 or 400 mg of caffeine.
As little as 100 mg increased false recall and false recognition — while true memory did not improve.
Meaning, caffeine didn’t improve what they actually remembered.
It increased the number of memories that weren't real.
Another study gave subjects 100 mg before an auditory-verbal learning test.
They listened to spoken word lists and were asked to recall them.
The caffeine group recalled fewer words.
Working memory shows the same pattern.
Working memory is what you use to hold information in mind for a few seconds, like a phone number or a short list.
A 2013 behavioral and fMRI study found that caffeine’s effects were more consistent with a detrimental effect at higher working-memory loads than with enhancement.
The same pattern appears in creativity.
In one experiment using caffeinated gum, creative fluency significantly decreased compared with placebo.
The pattern is consistent: caffeine trades depth for speed.
Caffeine makes you feel switched on.
It makes you attack the task in front of you.
But that is not the same as thinking better.
For a founder, in the AI era, that distinction matters.
Pushing through tasks is not the scarce skill.
Judgment is.
Elevate Research Community retweeted
Better get off the train. It isn't getting any easier
Tulip King 🌷@tulipkingOct 17North America
North AmericaConnected via North America App StoreAccount-level information, not a live location or per-post device.
Eli Lilly starts suing all the grey market US resellers of “research” peptides, cuts a nice GLP-1 deal with Medicare, in return FDA cracks down on Chinese makers of the drug - TLDR: Lilly is putting clamps around the unauthorized manufacturers and distributors of peptides before launching what will be the most profitable drug in existence, Retatrutide $LLY
You know what, Saturday QnA, any question goes, answer will be to the best of my ability, given the question has enough context behind it
Poor question: simple answer
Poor question but good degree and amount of context: better answer
Elevate Research Community retweeted
Two residues separate oxytocin from vasopressin. With these two, selectivity is the hard part. kimerachems.co/library/oxyto…
Elevate Research Community retweeted

Next Science@NextScienceOct 17
South Asia
South AsiaConnected via North America App StoreAccount-level information, not a live location or per-post device.
A Deadly Sting… or a Future Cancer Cure?
Scientists have found molecules in scorpion venom that may be able to attack triple-negative breast cancer, one of the hardest cancers to treat. In early lab tests, these compounds showed the ability to target and damage cancer cells, opening new hope for future treatments.
But this is still early research—no cure exists yet, and testing in humans is still needed. Still, the idea is striking: something so dangerous in nature might one day help save lives.
Source:
National Center for Biotechnology Information. (n.d.). Scorpion venom peptides and anticancer research on triple-negative breast cancer. PubMed Central.

ALT A Deadly Sting… or a Future Cancer Cure? Scientists have found molecules in scorpion venom that may be able to attack triple-negative breast cancer, one of the hardest cancers to treat. In early lab tests, these compounds showed the ability to target and damage cancer cells, opening new hope for future treatments. But this is still early research—no cure exists yet, and testing in humans is still needed. Still, the idea is striking: something so dangerous in nature might one day help save lives. Source:
National Center for Biotechnology Information. (n.d.). Scorpion venom peptides and anticancer research on triple-negative breast cancer. PubMed Central.
Elevate Research Community retweeted
GW-0742: EC50 of 1.1 nM at PPAR-delta, about thousandfold selective. Some of its effects still show up in tissue with no receptor. kimerachems.co/library/gw-07…
Elevate Research Community retweeted
Maybe we should start a competitor to Amazon 🤔
amazon is blocking grok @bots from ordering, and elon's answer is just have your bot buy it somewhere else.
one of my grok bots only handles my amazon returns, so i'm watching this one closely.
would you switch stores for your bot? đź›’
Elon, i think its time for an X Shop? đź‘€
Elevate Research Community retweeted
New Publication! Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis
Click on the image below to learn more.
Elevate Research Community retweeted
Nothing wrong with ever supporting other peptide companies. I always want to see everyone win. I’ve done business with @EliteresearchUS @KimeraChems @LifeIgniteRsrch @tonymission @PeptidePlugs @ThePepGuy & if you guys ever want to support me @BioLongevityUSA feel free to use my code as well: MattC
Elevate Research Community retweeted
Russian researchers are investigating a sea anemone venom peptide for anxiety and brain plasticity.
A 2026 study examined APHC3, a 56-amino-acid peptide isolated from the sea anemone Heteractis crispa.
Originally developed as a non-opioid analgesic candidate, APHC3 modulates TRPV1, an ion channel involved in pain, inflammation, and stress responses.
Researchers found:
• Enhanced long-term potentiation (LTP) in the hippocampus, a process involved in learning and memory.
• Changes in synaptic signaling consistent with altered neuronal plasticity.
• Intranasal APHC3 at 0.01 mg/kg increased time spent in the open arms of an elevated maze by 113% versus controls.
• Intramuscular administration produced stronger and more consistent anxiolytic-like effects.
The interesting part is how far this research has moved beyond pain.
Earlier Russian studies found APHC3 reduced inflammation and joint damage in animal models of arthritis.
A separate 2024 study also investigated its neuroprotective effects in cellular models involving alpha-synuclein, a protein associated with Parkinson’s disease.
Now researchers are examining its effects on anxiety-related behavior and hippocampal plasticity.
One marine peptide, three research directions: pain, neuroprotection, and stress responses.
These remain preclinical findings, not evidence of therapeutic efficacy in humans.
2026 study:
pubmed.ncbi.nlm.nih.gov/4174…
RT @rorynotsorry: Here’s IP question about Retatrutide. As I understand it, Eli Lily added two side chains to try and game the system. Coul…
This quoted post is unavailable.
Elevate Research Community retweeted
Our labels list the free-base molecular weight, even when the product is a salt. Mass spec reads the base mass. That's the number that should match. kimerachems.co/coas/
Elevate Research Community retweeted
FOXO4-DRI runs its sequence in reverse with D-amino acids. Same side chains, nothing for proteases to grab. kimerachems.co/library/foxo4…
Elevate Research Community retweeted

Krysia@Krysia830073Oct 10
United Kingdom
United KingdomConnected via United Kingdom App StoreAccount-level information, not a live location or per-post device.
Spare a Thought for Eli Lilly: LiveWell Allegedly Helped Itself to their Research
“Research use only” looks slightly awkward next to a physique transformation, injection guidance and a discount code. Lilly has collected the lot in its complaint against LiveWell over alleged consumer retatrutide sales.
Lilly also considers itself an injured party: it paid for the trials, says others are cashing in on the results, and fears being left with the reputational cleanup. Fortunately, its distress comes with legal representation
Link to full article below
Krysia@Krysia830073Oct 10United Kingdom
United KingdomConnected via United Kingdom App StoreAccount-level information, not a live location or per-post device.


















